March 12, 2026 a 07:43 pm
ABBV: Fundamental Ratio Analysis - AbbVie Inc.
AbbVie Inc. operates in the global pharmaceutical industry, offering a variety of treatments for autoimmune diseases, cancers, and more. Despite a challenging market, AbbVie has maintained a consistent pipeline of innovative therapies. The company's strategic investments and partnerships position it for future growth.
Fundamental Rating
The fundamental analysis of AbbVie Inc. presents a mixed outlook, reflected in the overall "C+" rating. While certain metrics are robust, others reveal areas of concern.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 1 | |
| Return on Assets | 4 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Historical Rating
The historical trends in the ratings offer insights into the company's performance over time.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-03-12 | 2 | 4 | 1 | 4 | 1 | 1 | 1 |
| Previous | 0 | 4 | 1 | 4 | 1 | 1 | 1 |
Analyst Price Targets
Analysts have set a range of targets, reflecting varied expectations about AbbVie's future market performance.
| High | Low | Median | Consensus |
|---|---|---|---|
| $299 | $223 | $258 | $256.15 |
Analyst Sentiment
The sentiment analysis provides an overview of analysts' recommendations, showing a prevailing positive outlook on the stock.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 26 | |
| Hold | 12 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
AbbVie Inc. stands out with a strong portfolio of pharmaceutical products and a promising pipeline. However, challenges such as high debt levels and reliance on key products may pose risks. Analyst sentiment is largely positive, suggesting confidence in the company's strategic direction. As AbbVie continues to diversify, it holds potential for sustainable growth in the evolving healthcare market.